Fig. 3: Estimated PE by PT₈₀ to the autologous acquired virus in AMP trials and in NHP studies.

a, Estimated PE by PT₈₀ to the acquired virus in AMP (black solid line) compared with the protection curve in three different sets of NHP (blue, mustard and green lines). b, PT₈₀ values associated with 50, 75 and 90% PE for AMP trials and each of the three sets of NHP. PT₈₀ values <2 were set to 1. Set A: n = 274 NHPs that received a single bnAb followed by SHIV challenge, bnAb titer data from all neutralization assays⁴; set B: only the NHPs in set A that received a CD4 binding site-targeting bnAb, excluding all that were challenged with SF162P3 and including only bnAb titer data from the TZM-bl target cell assay; and set C: all NHPs in set A but excluding those that received a membrane-proximal external region-targeting bnAb and all those challenged with SF162P3, and including only bnAb titer data from the TZM-bl target cell assay. The dashed horizontal lines are drawn at the y-axis values of 50, 75 and 90. These lines indicate the various curves that intersect a level of prevention efficacy of 50%, 75% or 90%.